[단독]”Kim Jin-wook, a professor at Harvard Medical School I met 20 years ago, believe in a long-term investment”

Candidate Jin-wook Kim, head of the Office of Crime Investigation for Senior Officials, is reported to have made a long-term investment in the company four years ago because of a relationship with a representative of a biotechnology company that he met while studying in the United States 20 years ago. The opposition, the power of the people, is related to the suspicion that candidate Kim raised, “Isn’t Kim using undisclosed information as a friend of the company’s representative in the process of purchasing 8343 shares of KOSDAQ Mikobimed?”

Candidate Kim’s personnel hearing preparatory group said on the day, “We have never made a transaction using important undisclosed information. The details will be explained in detail during the hearing process.” Candidate Kim himself said to the people around him about the suspicion, saying, “I am a failed investor and I am just a ruined ant.”

The JoongAng Ilbo heard about the story of Candidate Kim’s stock investment from an official from an official in the Establishment of the Airborne Agency, who requested anonymity.

An official from the preparatory group said, “Candidate Kim got to know Seong-Woo Kim, who served as a research professor at Harvard Medical School in the Korean community when studying at Harvard Law School in the United States in 2001-2002.” “It was recommended by Candidate Kim to invest in Biosys,” he explained. Nano Viosys is a comprehensive in vitro diagnostic medical device company established in 2009. Currently, it is listed on the KOSDAQ market under the name of Miko Biomed, which was merged in November 2017. Sungwoo Kim is currently the CEO of Miko Biomed.

According to the Electronic Disclosure System of the Financial Supervisory Service, Candidate Kim purchased 5813 shares of Nanobiosis for 8,300 won through a paid-in capital increase method allocated to a third party in March 2017. In addition to the existing shareholders, stocks are allocated to third parties. It is explained that because Candidate Kim accepted Kim’s recommendation, he was nominated as a third party and was able to participate in the capital increase. The purchase price (8300 won) is about 9% cheaper than the market price at the time (about 9100 won). This is because the discount rate is applied. Usually, a discount rate is applied because there is a risk that the number of shares will increase and the share price will fall if a capital increase is made. In this process, Candidate Kim explains that he had no knowledge of the merger with Miko Biomed.

It is said that Candidate Kim accepted President Kim’s invitation to invest because he highly appreciated the skills and character he experienced in the Korean community while studying abroad. Representative Kim obtained a Ph.D. in Neurobiology from Columbia University and was a professor at Harvard University Medical School. Candidate Kim is said to have judged that he has the ability to lead a bio company based on his experience. Candidate Kim explained that he made a long-term investment in the future, looking forward to 5-10 years.

The opposition party raised suspicion, “Is candidate Kim committed illegal activities such as being handed over confidential information about the company before investment?” An official of the people’s strength said, “We will thoroughly verify it at the hearing.”

Regarding this, an official from the establishment preparation group refuted, “If the undisclosed information was used, the stock price should have risen significantly immediately after the purchase, but on November 10, 2017, it had plunged to 4150 won.” In fact, Miko Biomed’s stock price moved sideways at a similar level until early 2020 after being cut in half. Since then, the stock has soared to 33,900 won during the intraday on July 24 as the stock was tied up as a theme stock for a novel coronavirus infection (Corona 19). However, Candidate Kim said he did not seek to realize profits because he had a long-term investment purpose.

Candidate Kim has purchased an additional 2,500 shares at an average of 25,000 won per share since mid-August last year, an official from the establishment preparation group said. The current share price is 11,300 won based on the closing price on the 5th, which has dropped significantly to 45% compared to the time of additional purchase. In the end, the overall return is said to be at the level of 0%. The report card that has been invested for nearly four years is actually negative.

Candidate Kim said that when he bought additional shares of Miko Biomed, he also bought 12 stocks including Samsung Electronics, Yuhan Corporation, and SK Telecom (currently equivalent to a total of 10 million won). According to the personnel hearing data recently submitted by Candidate Kim, Candidate Kim holds stocks in 13 listed companies. As of the end of last year, 8343 shares were worth 93.5 million won.

Reporter Minjoong Kim [email protected]